<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860560</url>
  </required_header>
  <id_info>
    <org_study_id>RP-HFR2013001Reg</org_study_id>
    <nct_id>NCT01860560</nct_id>
  </id_info>
  <brief_title>Non-Inferiority Trial of Acute HFT Versus nCPAP</brief_title>
  <official_title>Effect of High Flow Nasal Cannula (Flowrest®) on Mild-Moderate Sleep Disordered Breathing: A Non-Inferiority Study Versus Nasal Continuous Positive Airway Pressure (CPAP) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vapotherm, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vapotherm, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Order randomized crossover non-inferiority study evaluating the acute efficacy of High Flow&#xD;
      Therapy (HFT) as compared to nasal Continuous Positive Airway Pressure therapy (CPAP) in the&#xD;
      management of apnea / hypopnea index (AHI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to evaluate the acute efficacy of a single night of High Flow Therapy (HFT) to treat&#xD;
      mild-moderate predominantly obstructive Sleep Disordered Breathing, as compared to nasal&#xD;
      Continuous Positive Airway Pressure (CPAP) therapy. Subjects will be order-randomized to&#xD;
      receive HFT or CPAP in the laboratory, undergo a washout period, and return for the&#xD;
      alternative therapy in the laboratory. The hypothesis is that HFT will be non-inferior to&#xD;
      CPAP in controlling Apnea/Hypopnea events in this subject set during this study.&#xD;
&#xD;
      Primary outcome will be Apnea / Hypopnea Index (AHI) change on therapy as compared to&#xD;
      baseline diagnostic polysomnography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AHI Change (Therapy v Baseline)</measure>
    <time_frame>Acute - single night therapy exposure</time_frame>
    <description>Evaluate the change in AHI from baseline for HFT v CPAP therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulse Oxygen Saturation</measure>
    <time_frame>Acute single night therapy exposure</time_frame>
    <description>Evaluate the mean, absolute minimum, absolute event-related nadir and mean nadir of pulse oxygen saturation during therapeutic polysomnography of HFT v CPAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Architecture (WASO, %W, N1, N2, N3, REM, SL, RL, AI)</measure>
    <time_frame>Acute single night therapy exposure</time_frame>
    <description>Evaluate changes in sleep architecture on HFT and CPAP therapy as compared to baseline diagnostic polysomnography. Specifically, evaluate any difference between the therapies on %Wake Time (of SPT), % time in stages N1, N2, N3, REM (of TST), Minutes of Wake After Sleep onset, Sleep latency and REM Latency. Any difference in overall non-respiratory arousal index will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Event Related Arousals</measure>
    <time_frame>Acute single night therapy exposure</time_frame>
    <description>Compare the incidence of RERA on HFT and CPAP therapy as compared to diagnostic polysomnography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Disturbance Index (RDI)</measure>
    <time_frame>Acute single night therapy exposure</time_frame>
    <description>Evaluate the RDI on HFT v CPAP therapy as compared to the diagnostic polysomnography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Mild-Moderate Obstructive Sleep Disordered Breathing</condition>
  <arm_group>
    <arm_group_label>CPAP First / HFT Second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects to receive both therapies, order-randomized to receive Continuous Positive Airway Pressure (CPAP) therapy study first, followed by a washout period, and a follow-on High-Flow Therapy (HFT) therapy study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFT First / CPAP Second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects to receive both therapies, order-randomized to receive High-Flow Therapy (HFT) therapy study first, followed by a washout period, and a follow-on Continuous Positive Airway Pressure (CPAP) therapy study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-Flow Therapy</intervention_name>
    <description>Blower-based High Flow Therapy delivered by nasal cannula</description>
    <arm_group_label>CPAP First / HFT Second</arm_group_label>
    <arm_group_label>HFT First / CPAP Second</arm_group_label>
    <other_name>Vapotherm Flowrest High Flow Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure</intervention_name>
    <description>CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.</description>
    <arm_group_label>CPAP First / HFT Second</arm_group_label>
    <arm_group_label>HFT First / CPAP Second</arm_group_label>
    <other_name>Respironics Synchrony Lab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Previous diagnosis of primarily obstructive mild-moderate Sleep Disordered Breathing&#xD;
             during in-laboratory polysomnography&#xD;
&#xD;
          -  Ability to read and understand English Language&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable medical illness within the last month (30 days)&#xD;
&#xD;
          -  Acute / recent upper airway infection&#xD;
&#xD;
          -  Prior use of non-continuous positive airway pressure medical technology therapies&#xD;
             prescribed by a physician for the management of obstructive sleep disordered breathing&#xD;
             (e.g., Provent®, Winx™, mandibular advancement oral appliances, etc.)&#xD;
&#xD;
          -  Prior use or exposure to CPAP / Bi-Level / or other non-invasive ventilatory&#xD;
             modalities&#xD;
&#xD;
          -  Craniofacial or other anatomical anomalies that may predispose patients to upper&#xD;
             airway obstruction, or obvious blockage to nasal air flow&#xD;
&#xD;
          -  Patients using opioids or amphetamines will be excluded from the study.&#xD;
&#xD;
          -  Enhanced oxygen requirement (i.e., FiO2&gt;0.21)&#xD;
&#xD;
          -  Patients requiring Bi-Level therapy upon CPAP titration attempt&#xD;
&#xD;
          -  Surgery since the diagnostic PSG&#xD;
&#xD;
          -  Significant recent sedative/hypnotic use likely, in the opinion of the principle&#xD;
             investigator, to impair ventilatory control or impact the subsequent titration of&#xD;
             either CPAP therapy or Flowrest therapy (including benzodiazepines, antihistamines,&#xD;
             imidazopyridines)&#xD;
&#xD;
          -  Significant use of stimulant medications likely, in the opinion of the principle&#xD;
             investigator, likely to alter ventilatory or upper airway control and impact the&#xD;
             subsequent titration of either CPAP therapy or Flowrest therapy (including&#xD;
             amphetamines, high dose caffeine, etc.)&#xD;
&#xD;
          -  Significant neurologic or cardiac pathology likely to seriously impact respiratory&#xD;
             effort or ventilatory control (e.g., post CVA with ventilatory impairment)&#xD;
&#xD;
          -  Presence of significant sleep disorders likely to induce hypersomnolence or interfere&#xD;
             with the ability to titrate CPAP therapy or Flowrest therapy (including narcolepsy,&#xD;
             PLMS/RLS, severe chronic insomnia, non-OSA obesity hypoventilation syndrome, etc.)&#xD;
&#xD;
          -  Unsuitable for inclusion in the opinion of the investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Dungan, MPhil Med</last_name>
    <role>Study Director</role>
    <affiliation>Vapotherm, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sleep Disorders Centers of the Mid-Atlantic</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OSA</keyword>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>High Flow Therapy</keyword>
  <keyword>CPAP</keyword>
  <keyword>HFT</keyword>
  <keyword>Continuous Positive Airway Pressure</keyword>
  <keyword>Mild OSA</keyword>
  <keyword>Moderate OSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

